Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing
This study confirms the clinical efficacy and safety of avelumab, showing improved outcomes over JAVELIN Bladder 100 and suggesting that morning infusions may offer a survival benefit in this context. Further research is needed to optimize treatment sequencing and explore the impact of infusion timing in ICI strategies.
Authors
- Rita Carrilho Pichel (ORCID: https://orcid.org/0000-0002-4650-5595)
- João Gramaça (ORCID: https://orcid.org/0000-0001-6968-0436)
- Gonçalo Cunha (ORCID: https://orcid.org/0000-0002-0111-0661)
- Joana Marinho (ORCID: https://orcid.org/0000-0003-3665-4666)
- Helena Guedes
- I. Dunoes
- Nadja Maria Mourão (ORCID: https://orcid.org/0000-0003-3990-0201)
- Ana Fortuna (ORCID: https://orcid.org/0000-0001-5368-2410)
- Luís Costa (ORCID: https://orcid.org/0000-0002-4782-7318)
- Rita Freitas (ORCID: https://orcid.org/0009-0002-7059-1312)
- Lisa Gonçalves (ORCID: https://orcid.org/0000-0002-3431-5217)
- Telma Maria Araújo Moura Lemos (ORCID: https://orcid.org/0000-0001-7118-2145)
- Pedro Simões (ORCID: https://orcid.org/0000-0002-4734-7621)
- Joana Alves Luís
- Ana Sofia Spencer
Institutions
- University of Trás-os-Montes and Alto Douro (PT)
- Instituto Português de Oncologia de Coimbra Francisco Gentil (PT)
- Lusíada University of Lisbon (PT)
- Administração Regional de Saúde de Lisboa e Vale do Tejo (PT)
- Centro Hospitalar de Vila Nova de Gaia (PT)
- Escola Secundária de Loulé (PT)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-06
- DOI
- https://doi.org/10.3390/cancers17050898
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02